Aug, 2024

U.S.A.
News / Therapeutic Area News
China's National Medical Products Administration (NMPA) Approves PADCEV™ (enfortumab vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer
- Approval based on the global EV-301 and China EV-203 trials, where enfortumab vedotin significantly improved overall survival (OS) and objective response rate (ORR) respectively in patients...
Read More

Jul, 2024

U.S.A.
News / Therapeutic Area News
Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer
- If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted therapy approved in the European Union - A decision on the EU marketing authorization is...
Read More
U.S.A.
News / Therapeutic Area News
Astellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
- If approved, enfortumab vedotin in combination with pembrolizumab will be the first and only treatment to offer an alternative to platinum-containing chemotherapy, the current standard of care...
Read More

May, 2024

U.S.A.
News / Therapeutic Area News
U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE
If approved, the investigational therapy would offer a new treatment option for patients with advanced gastric and gastroesophageal junction cancers as the first and only CLDN18.2-targeted therapy...
Read More
U.S.A.
News / Therapeutic Area News
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
16 abstracts feature new data and post-hoc analyses of pivotal trials across several types of hard-to-treat cancers TOKYO, May 13, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President...
Read More